We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Register Free
Advertise with Us
Latest Issue
Latest Issue
LGC Clinical Diagnostics

Download Mobile App




Illustration

Israeli Scientists to Announce Development of Coronavirus Vaccine

 Over 50 experienced PhD scientists from the Israel Institute for Biological research (IIBR; Ness-Ziona, Israel) are working to produce a vaccine and antibody for the novel coronavirus. More...
16 Mar 2020
Illustration

Researchers Discover World’s First Human Antibody that Could Inhibit New Coronavirus (SARS-CoV-2)

 Researchers have developed the world’s first human antibody that could inhibit the new coronavirus (SARS-CoV-2) and ‘offers potential for prevention and treatment of COVID-19’. A team of 10 scientists from the University of Utrecht (Utrecht, the Netherlands), the Erasmus Medical Centre (Rotterdam, the Netherlands), and biotech company Harbor BioMed (Cambridge, MA, USA) have published their research online on BioRxiv where it is under peer review before being published by the prestigious journal Nature. More...
14 Mar 2020
Image: COVID-19 IgM-IgG Rapid Test (Photo courtesy of BioMedomics, Inc.)

BioMedomics Launches COVID-19 IgM-IgG Rapid Test for Novel Coronavirus

 BioMedomics, Inc. (Morrisville, NC, USA) has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection. The new rapid IgM-IgG combined antibody test for COVID-19 is used to qualitatively detect IgG and IgM antibodies of the novel coronavirus in human serum, plasma or whole blood in vitro. These proteins indicate that a person’s immune system has responded to infection with the COVID-19 virus. It is one of the world’s first rapid tests for coronavirus utilizing this technology. More...
14 Mar 2020
Illustration

Tiziana Life Sciences Accelerate Development of Potential Covid-19 Drug

 Tiziana Life Sciences (London, UK), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The company has entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in 2017. More...
14 Mar 2020
Illustration

Emergent BioSolutions Collaborates with Novavax for Experimental Vaccine Candidate for Coronavirus Disease

 Emergent BioSolutions Inc. (Gaithersburg, MD, USA) has entered into an agreement with Novavax, Inc. (Gaithersburg, MD, USA) whereby Emergent will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services to support bringing into the clinic Novavax’s novel experimental vaccine candidate to protect against coronavirus disease (COVID-19). Under the terms of the agreement, Emergent will produce the COVID-19 experimental vaccine candidate, which is based on the proprietary recombinant protein nanoparticle technology platform of Novavax and utilizing their proprietary Matrix-M™ adjuvant to enhance immune responses. Emergent has initiated work for this program anticipating that the COVID-19 experimental vaccine candidate will be used in a Phase 1 clinical study within the next four months. More...
14 Mar 2020
Illustration

Vir Biotechnology Partners with NIH and Biogen for Developing Coronavirus Antibodies

 Vir Biotechnology, Inc. (San Francisco, CA, USA) has entered into a collaboration with Biogen Inc. (Cambridge, MA, USA) for the development and clinical manufacturing of human monoclonal antibodies (mAbs) for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. More...
14 Mar 2020
Image: Hologic`s Panther Fusion System (Photo courtesy of Hologic, Inc.)

Hologic’s Panther Fusion System Shows Feasibility for Detection of SARS-Coronavirus-2 (SARS-CoV-2)

 Researchers at the Hannover Medical School (Hannover, Germany) have developed a molecular assay for detecting the novel coronavirus SARS-CoV-2 (previously 2019-nCoV) on Hologic, Inc.’s (Marlborough, MA, USA) automated Panther Fusion system. More...
10 Mar 2020
Visit expo >
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA
New
Hepatitis B Virus Test
HBs Ab – ELISA

In Other News

LabMedica

About Us
Advertising Info
Subscription
Client Login
Privacy Policy
Cookie Policy
Journal Info
Contact Us

Channels

Clinical Chem.
Molecular Diagnostics
Hematology
Immunology
Microbiology
Pathology
Technology
BioResearch
Industry
Events
Focus

Features

Events Product Showcase LinkXpress Whitepapers archive Video Library

Partner Sites

LabMedica ExpoHospiMedica.com Globetech.net

Archive:

BioResearch
COVID-19

2024
ADLM Medlab 2023
AACC EUROMEDLAB Medlab 2022
AACC

 

ECCMID EUROMEDLAB Medlab 2021
AACC MEDLAB 2020
AACC COV MEDLAB
Copyright © 2000-2024 Globetech Media. All rights reserved.
MOBILE | FULL SITE